AlloVir, Inc. (ALVR)

0.7971 -0.0029 (-0.36%) At close: 04:00PM EDT

AlloVir, Inc.

1100 Winter Street
Waltham, MA 02451
United States
617 433 2605
https://www.allovir.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 112

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David L. Hallal	Executive Chairman of the Board	200k	N/A	1966
Dr. Diana M. Brainard M.D.	CEO & Director	636.63k	N/A	1972
Mr. Vikas Sinha C.A., CPA, M.B.A.	President, CFO & Director	373.04k	N/A	1963
Mr. Edward Miller J.D.	General Counsel & Secretary	461.66k	N/A	1965
Mr. Brett R. Hagen	Chief Accounting Officer	N/A	N/A	1973
Mr. Dana M. Alexander	Senior Vice President of Technical Operations	N/A	N/A	1976
Dr. Ann M. Leen Ph.D.	Chief Scientific Officer	N/A	N/A	1977
Ms. Cintia Piccina Pharm.D.	Chief Commercial Officer	N/A	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Corporate governance

AlloVir, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.